Alfredo Addeo
@alfdoc2.bsky.social
Medical oncology at university hospital Geneva . Passioned about science
Reposted by Alfredo Addeo
👉 Submit an abstract to the European Lung Cancer Congress 2026! Share your research at this leading multidisciplinary congress and drive innovation in the field of thoracic oncology.
#esmomeetings #ELCC26
⏰ Submission deadline: 13 January 2026.
🔗 https://ow.ly/YEJp50Xomo0
#esmomeetings #ELCC26
⏰ Submission deadline: 13 January 2026.
🔗 https://ow.ly/YEJp50Xomo0
November 17, 2025 at 4:00 PM
👉 Submit an abstract to the European Lung Cancer Congress 2026! Share your research at this leading multidisciplinary congress and drive innovation in the field of thoracic oncology.
#esmomeetings #ELCC26
⏰ Submission deadline: 13 January 2026.
🔗 https://ow.ly/YEJp50Xomo0
#esmomeetings #ELCC26
⏰ Submission deadline: 13 January 2026.
🔗 https://ow.ly/YEJp50Xomo0
Reposted by Alfredo Addeo
#ESMO25: Paradigm shifts are occurring in the management of metastatic mutated #NSCLC. Alfredo Addeo describes some of the innovative #TargetedTherapies and combinations that are improving patient outcomes.
#ESMODailyReporter ➡️ https://ow.ly/IWOr50XeTfh
#LungCancer
Alfredo Addeo
#ESMODailyReporter ➡️ https://ow.ly/IWOr50XeTfh
#LungCancer
Alfredo Addeo
October 21, 2025 at 12:01 PM
#ESMO25: Paradigm shifts are occurring in the management of metastatic mutated #NSCLC. Alfredo Addeo describes some of the innovative #TargetedTherapies and combinations that are improving patient outcomes.
#ESMODailyReporter ➡️ https://ow.ly/IWOr50XeTfh
#LungCancer
Alfredo Addeo
#ESMODailyReporter ➡️ https://ow.ly/IWOr50XeTfh
#LungCancer
Alfredo Addeo
Reposted by Alfredo Addeo
A True Game Changer in Targeted Therapy for Lung Cancer - Alfredo Addeo
@alfdoc2.bsky.social
@jillfeldman4.bsky.social
oncodaily.com/science/targ...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TargetedTherapy #LungCancer #TKIs
@alfdoc2.bsky.social
@jillfeldman4.bsky.social
oncodaily.com/science/targ...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TargetedTherapy #LungCancer #TKIs
Alfredo Addeo: A True Game Changer in Targeted Therapy for Lung Cancer - OncoDaily
Alfredo Addeo: A True Game Changer in Targeted Therapy for Lung Cancer / Alfredo Addeo, CA: A Cancer Journal for Clinicians, cancer, Claudio De Vito, Giuseppe
oncodaily.com
July 18, 2025 at 11:38 PM
A True Game Changer in Targeted Therapy for Lung Cancer - Alfredo Addeo
@alfdoc2.bsky.social
@jillfeldman4.bsky.social
oncodaily.com/science/targ...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TargetedTherapy #LungCancer #TKIs
@alfdoc2.bsky.social
@jillfeldman4.bsky.social
oncodaily.com/science/targ...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TargetedTherapy #LungCancer #TKIs
Reposted by Alfredo Addeo
Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival.
Read the opinion by @alfdoc2.bsky.social in the #ESMODailyReporter
🔗 buff.ly/3NXrdAg
#SCLC #LungCancer
Read the opinion by @alfdoc2.bsky.social in the #ESMODailyReporter
🔗 buff.ly/3NXrdAg
#SCLC #LungCancer
June 13, 2025 at 2:45 PM
Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival.
Read the opinion by @alfdoc2.bsky.social in the #ESMODailyReporter
🔗 buff.ly/3NXrdAg
#SCLC #LungCancer
Read the opinion by @alfdoc2.bsky.social in the #ESMODailyReporter
🔗 buff.ly/3NXrdAg
#SCLC #LungCancer
Reposted by Alfredo Addeo
Don't miss the new #LungCancerConsidered in Italian! @alfdoc2.bsky.social hosts a discussion with Dr. Cecilia Pompili & Dr. Francesco Passiglia to talk about treating resectable Stage III NSCLC & new therapy options.
🎧 Listen now: bit.ly/ItalianVTB
#LungCancer #NSCLC #Oncology #VTB
🎧 Listen now: bit.ly/ItalianVTB
#LungCancer #NSCLC #Oncology #VTB
LCC in Italian: Virtual Tumor Board – Resectable Stage III NSCLC | IASLC
As part of IASLC's ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a discussion in Italian with Dr. Cecilia Pompili and Dr. Franceso ...
bit.ly
April 11, 2025 at 4:34 PM
Don't miss the new #LungCancerConsidered in Italian! @alfdoc2.bsky.social hosts a discussion with Dr. Cecilia Pompili & Dr. Francesco Passiglia to talk about treating resectable Stage III NSCLC & new therapy options.
🎧 Listen now: bit.ly/ItalianVTB
#LungCancer #NSCLC #Oncology #VTB
🎧 Listen now: bit.ly/ItalianVTB
#LungCancer #NSCLC #Oncology #VTB
just hot off the press, our review "Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back". Congrats to all the co-authors , DrBorgeaud Dr Mariniello, Dr Kim, Dr Weiner, Dr Frisone. Here the free access link.springer.com/article/10.1...
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back - BioDrugs
Immunotherapy with checkpoint inhibitors has become the cornerstone of systemic treatment for non-oncogene addicted non-small-cell lung cancer. Despite its pivotal role, a significant proportion of pa...
link.springer.com
February 16, 2025 at 9:26 AM
just hot off the press, our review "Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back". Congrats to all the co-authors , DrBorgeaud Dr Mariniello, Dr Kim, Dr Weiner, Dr Frisone. Here the free access link.springer.com/article/10.1...
Reposted by Alfredo Addeo
IASLC #WCLC2025 is upon us! Your co-chairs cannot wait to welcome you #NoemiReguart 🇪🇸 #IsabelleOpitz🇨🇭 #UmbertoMalapelle 🇮🇹 & a familiar face from🇮🇪
Registration & abstract submissions are OPEN!
Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC
Registration & abstract submissions are OPEN!
Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC
February 13, 2025 at 10:15 PM
IASLC #WCLC2025 is upon us! Your co-chairs cannot wait to welcome you #NoemiReguart 🇪🇸 #IsabelleOpitz🇨🇭 #UmbertoMalapelle 🇮🇹 & a familiar face from🇮🇪
Registration & abstract submissions are OPEN!
Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC
Registration & abstract submissions are OPEN!
Join us in Barcelona | Sept 6–9, 2025 @iaslc.bsky.social @oncoalert.bsky.social #LCSM bit.ly/IASLCWCLC
Reposted by Alfredo Addeo
Leaving X
I can’t continue to support X with a clear conscience.
I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.
I can’t continue to support X with a clear conscience.
I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.
February 7, 2025 at 8:27 AM
Leaving X
I can’t continue to support X with a clear conscience.
I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.
I can’t continue to support X with a clear conscience.
I hope BlueSky replaces it. But I don’t think it will do so quickly unless we drop X, as opposed to us having feet in both camps.
Reposted by Alfredo Addeo
@drsanjaypopat.bsky.social kicks off @btog.bsky.social Essential Update in therapeutic options for stage 4 NSCLC
✅ all topics covered
✅ stellar speaker line up
✅ full house
👊👊👊
✅ all topics covered
✅ stellar speaker line up
✅ full house
👊👊👊
January 31, 2025 at 9:18 AM
@drsanjaypopat.bsky.social kicks off @btog.bsky.social Essential Update in therapeutic options for stage 4 NSCLC
✅ all topics covered
✅ stellar speaker line up
✅ full house
👊👊👊
✅ all topics covered
✅ stellar speaker line up
✅ full house
👊👊👊
Reposted by Alfredo Addeo
Samreen Ahmed on uncommon EGFR mutations.
Referencing the lovely paper & beautiful figure by @alfdoc2.bsky.social
Distills treatment options really well
Referencing the lovely paper & beautiful figure by @alfdoc2.bsky.social
Distills treatment options really well
January 31, 2025 at 10:02 AM
Samreen Ahmed on uncommon EGFR mutations.
Referencing the lovely paper & beautiful figure by @alfdoc2.bsky.social
Distills treatment options really well
Referencing the lovely paper & beautiful figure by @alfdoc2.bsky.social
Distills treatment options really well
Pleased to share our brand-new certification for our Lung Cancer Centre—a unique quality label within the Canton of Geneva. This achievement has been made possible thanks to an incredible team effort, unwavering commitment, and strong support.#University Hospital Geneva
January 29, 2025 at 8:51 PM
Pleased to share our brand-new certification for our Lung Cancer Centre—a unique quality label within the Canton of Geneva. This achievement has been made possible thanks to an incredible team effort, unwavering commitment, and strong support.#University Hospital Geneva
Reposted by Alfredo Addeo
The HTIBM: lessons learned. Episode 6 - Me and Cetnar dance again. @onclive.bsky.social and I were still feeling out what How This is Building Me was a little. I had an evolving people centered model but onclive didn’t want to waste an expert opportunity either.
December 13, 2024 at 4:44 AM
The HTIBM: lessons learned. Episode 6 - Me and Cetnar dance again. @onclive.bsky.social and I were still feeling out what How This is Building Me was a little. I had an evolving people centered model but onclive didn’t want to waste an expert opportunity either.
Reposted by Alfredo Addeo
Nice article on movement from Ex to 🦋
www.nytimes.com/2024/12/07/o...
www.nytimes.com/2024/12/07/o...
Opinion | Bluesky Is Different From X. For Now.
Users are looking for a more curated experience on a platform that is not constantly trying to get them to interact with brands.
www.nytimes.com
December 7, 2024 at 4:17 PM
Nice article on movement from Ex to 🦋
www.nytimes.com/2024/12/07/o...
www.nytimes.com/2024/12/07/o...
Lovely team-building karaoke all together—it was so much fun! Special thanks to my Neapolitan friends for singing along to Napul’è!
December 6, 2024 at 6:25 AM
Lovely team-building karaoke all together—it was so much fun! Special thanks to my Neapolitan friends for singing along to Napul’è!
Reposted by Alfredo Addeo
Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
Management of severe immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors
AbstractBackground. Immune checkpoint inhibitors (ICIs) are associated with severe immune-related adverse events (s-irAEs) that result in hospitalization,
academic.oup.com
December 1, 2024 at 12:36 AM
Pleased to share our paper on the impact of severe irAEs in adv NSCLC #TheOncologist
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
- 3211pts, ConcertAI database
- 8.6% s-irAEs: diarrhea 3.5%, pneu 1.4%
- s-irAEs req steroids/immunosuppression=53%⬆️risk death v no irAE
@oncoalert.bsky.social #MedSky #OncSky #LCSM
academic.oup.com/oncolo/advan...
Reposted by Alfredo Addeo
Howdy, folks! I've arrived! #LCSM @n8pennell.bsky.social @antoniopassaro.bsky.social @stephenvliu.bsky.social
November 30, 2024 at 4:56 PM
Howdy, folks! I've arrived! #LCSM @n8pennell.bsky.social @antoniopassaro.bsky.social @stephenvliu.bsky.social
Reposted by Alfredo Addeo
Impact of cycle 1 irAEs on ICI outcomes:
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors
AbstractBackground. Associations between immune-related adverse events (irAEs) from checkpoint inhibitor therapy and outcomes have been previously evaluate
academic.oup.com
November 29, 2024 at 2:16 PM
Impact of cycle 1 irAEs on ICI outcomes:
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
- 683pts from SWOG DART trial
- g1-2 irAEs = ⬆️OS HR 0.61 p < 0.001
- g3+ irAEs = ⬇️OS HR 1.41 p= .025
- g1-2 derm irAE = ⬆️OS v other g1-2 irAE HR 0.67 p=0.002
Congrats @eladsharonmd.bsky.social @oncoalert.bsky.social
academic.oup.com/jnci/advance...
Reposted by Alfredo Addeo
I know many other have done these but I’ve collected almost 100 people and my personal list is hard to share.
go.bsky.app/2mRM9TD
go.bsky.app/2mRM9TD
November 24, 2024 at 2:14 PM
I know many other have done these but I’ve collected almost 100 people and my personal list is hard to share.
go.bsky.app/2mRM9TD
go.bsky.app/2mRM9TD
Reposted by Alfredo Addeo
Why strew'st thou sugar on that bottled spider, Whose deadly web ensnareth thee about?
Richard III 1.3
#ShakespeareSunday #GameofThrones
Richard III 1.3
#ShakespeareSunday #GameofThrones
a man is talking to a woman and says my little birds are everywhere .
ALT: a man is talking to a woman and says my little birds are everywhere .
media.tenor.com
November 24, 2024 at 3:36 PM
Why strew'st thou sugar on that bottled spider, Whose deadly web ensnareth thee about?
Richard III 1.3
#ShakespeareSunday #GameofThrones
Richard III 1.3
#ShakespeareSunday #GameofThrones
Reposted by Alfredo Addeo
November 23, 2024 at 12:25 PM